Zhi Tong Cai Jing·2025-11-24 07:21Core Viewpoint - Mirxes has signed a memorandum of understanding with Watson Bio to collaborate in molecular diagnostics and vaccine development, aiming to expand into ASEAN and global markets [1] Group 1: Company Developments - Mirxes' stock rose nearly 8% in early trading, currently up 2.48% at HKD 53.8, with a trading volume of HKD 18.2942 million [1] - The partnership with Watson Bio signifies a strategic collaboration between a leading precision diagnostics company and a top vaccine developer, establishing a solid foundation for an RNA-based preventive and precision medical platform [1] Group 2: Product Approval and Market Impact - In October, Mirxes' core product GASTROClear received approval from the National Medical Products Administration (NMPA) in China, becoming the world's first and only approved molecular diagnostic IVD product for gastric cancer screening [1] - This milestone represents a commercial breakthrough for the company, transitioning from "0 to 1," and is expected to lead to a revaluation of the company's worth [1] - The approval allows Mirxes to enter the vast gastric cancer screening market in China, serving as a significant catalyst for short-term performance [1]